Fortis Drops plan to sell stake in RHT Health Trust, RHTTM

Published On 2019-06-18 08:27 GMT   |   Update On 2019-06-18 08:27 GMT

New Delhi: Country's one of the leading super speciality hospital chain, Fortis Healthcare (FHL) has recently scrapped the plan to sell stakes in RHT Health Trust and RHT Health Trust Manager Pte Ltd (RHTTM). According to media reports, on June 15 Fortis decided to close the bidding and search process to explore the possibility of a sale of interest in RHT Health Trust and RHT Health Trust Manager Pte Ltd (RHTTM).


However, a couple of months ago FHL had initiated talks with potential buyers to sell its stake in Singapore listed RHT. Medical dialogues had earlier reported that a couple and a month after acquiring the assets of Religare Health Trust (RHT) for Rs 4650 crore, Fortis Healthcare Ltd. (FHL) had initiated talks with potential buyers to sell its stake in Singapore listed RHT. The sale proceeds were likely to be put back into the Fortis business in India in order to make it more successful.


Prior to this, Fortis had completed the acquisition of RHT Health Trust (RHT) assets and had entered into definitive agreements with RHT to acquire the entire portfolio of assets of the Singapore-listed entity for an enterprise value of Rs 4,650 crore.


Also Read: Fortis Healthcare to sell stake in Singapore listed Rs 4650 crore RHT Trust


In an earlier filing to bourses, the company had said its group firm Fortis Healthcare International Ltd had commenced deliberations to explore the sale of interest in RHT and RHTTM.


“No firm proposal which is commercially viable was received and no agreement (binding or non- binding) has been reached with any of these parties in connection with the Potential Transactions or any other transaction involving RHT and/or RHTTM," FHL said.


Also Read: Fortis Healthcare to sell stake in Singapore listed Rs 4650 crore RHT Trust




RHTTM is a subsidiary of the Stellant. Stellant and Fortis Healthcare International Ltd (FHIL) are direct/ indirect wholly-owned subsidiaries of the company, Fortis Healthcare said in a filing to BSE.



"Pursuant to an open invitation to interested parties to submit proposals in connection with the potential transactions, a process to evaluate proposals was undertaken with professional advisers, and preliminary discussions were held with certain third parties concerning the Potential Transactions", it added.


"Since the process to explore the potential transaction was inconclusive, it was decided to close the bidding and search process", it further added.


Fortis has an aggregate interest in 27.82% of the units in RHT, comprising 25.14% held by FHIL and 2.68% held by the trustee-manager, a unit of Stellant. FHIL and Stellant are wholly-owned subsidiaries of FHL.


Also Read: Fortis Healthcare International to sell entire stake in MSCL
Article Source : With inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News